経頭蓋磁気刺激装置の世界市場規模：タイプ別、用途別、エンドユーザー別、地域範囲別、予測

経頭蓋磁気刺激装置の市場規模と予測

経頭蓋磁気刺激装置の市場規模は、2024年に11億3,000万米ドルと評価され、2026年から2032年にかけてCAGR 8.45%で成長し、2032年には21億6,000万米ドルに達すると予測されています。

経頭蓋磁気刺激装置（TMS）は、電磁場を用いて脳の神経細胞を刺激する非侵襲的な医療処置です。この技術では、磁気コイルを頭皮に当てることで磁場を発生させ、特定の脳領域に電流を誘導します。TMSは主に神経細胞の活動を調節するために使用され、さまざまな神経学的および精神医学的状態における治療の可能性が広く調査されています。

TMSは、特に薬物療法や精神療法のような伝統的な治療法に反応しない患者の大うつ病性障害の治療に最も顕著に応用されています。

また、不安障害、心的外傷後ストレス障害（PTSD）、慢性疼痛など、他の疾患の治療にも応用が検討されています。TMSは通常外来で行われ、患者は数週間にわたって複数回のセッションを受ける。

さらに、TMSは脳機能と脳結合の研究に用いられ、神経疾患の理解を深めるのに役立っています。

TMSの将来の展望は有望であり、治療応用の拡大と有効性の向上を目指した研究が進行中です。技術の進歩により、脳領域のより正確なターゲティングや、特定の患者のニーズに基づいた個別の治療プロトコルが可能になるかもしれないです。

経頭蓋磁気刺激装置市場はCAGR 8.45%で成長し、2032年末までに21億6,000万米ドルに達すると推定されます。

経頭蓋磁気刺激装置の世界市場力学

経頭蓋磁気刺激装置の世界市場を形成している主な市場力学は以下のとおりです：

主な市場促進要因

うつ病と精神障害の有病率の増加：大うつ病性障害やその他の精神疾患と診断される患者数の増加が、特に従来の治療に抵抗性のある患者に対するTMSのような効果的な治療に対する需要を促進しています。世界保健機関（WHO）によると、2022年現在、世界中で約2億8,000万人がうつ病を患っています。米国では、国立精神衛生研究所（NIMH）の報告によると、2020年には推定2,100万人の成人が少なくとも1回は大うつ病エピソードに罹患しており、これは米国成人の8.4％に相当します。

技術の進歩：脳領域のより正確なターゲティングや携帯機器の開発など、TMS技術における絶え間ない技術革新は、治療成果を高め、TMSの応用範囲を拡大し、市場の成長を後押ししています。もう1つの主要プレーヤーであるブレインズウェイは、2024年1月に成人の不安性うつ病治療用のDeep TMS H7コイルを発売し、同社の技術の応用範囲を拡大しました。

認識と受容の高まり：非侵襲的な治療オプションとしてのTMSの利点と有効性に関する医療提供者と患者の意識の高まりは、採用率の上昇につながり、市場拡大に寄与します。米国精神医学会（APA）は2022年に大うつ病性障害の治療ガイドラインを更新し、少なくとも1種類の抗うつ薬に反応しなかった患者に対するセカンドライン治療としてTMSを推奨しています。

有利な規制環境：米国のFDAのような保健当局による支持的な規制政策と承認は、TMS機器の商業化と採用を促進し、市場の成長を促します。欧州医薬品庁（EMA）は2024年にTMS用医療機器の臨床調査に関するガイドラインを更新し、欧州市場における新規TMS機器の承認プロセスを合理化しました。

主な課題

限られた保険適用：TMS治療に対する不十分な償還政策と限定的な保険適用が、患者のアクセスと取り込みを妨げており、市場成長の課題となっています。

認識とトレーニングの欠如：患者と医療従事者双方の認識不足と、TMSを実施するための専門的トレーニングの必要性が、TMSの普及と受容を制限しています。

さまざまな臨床結果：治療結果にばらつきがあり、さまざまな患者集団で一貫した有効性を確立するには、より広範で長期的な臨床試験が必要であるため、信頼できる治療法としてのTMSの信頼性に影響を与えます。

規制と承認のハードル：厳しい規制要件と、新しいTMS機器やアプリケーションの承認プロセスに時間がかかるため、市場参入と技術革新が遅れ、市場拡大に課題があります。

主要動向

個別化TMS治療：神経画像とAIの開発により、個々の脳パターンに合わせた個別化TMSプロトコルの開発が可能になり、治療効果と患者の転帰が改善されつつあります。2024年9月にネイチャー・ニューロサイエンス誌に掲載された研究によると、個々の脳の結合パターンに基づくパーソナライズドTMSプロトコルは、標準的なプロトコルに比べて大うつ病性障害の治療成績が40％改善しました。

デジタルヘルスプラットフォームとの統合：遠隔医療や遠隔モニタリングなどのデジタルヘルスエコシステムにTMS療法を組み込むことで、患者のアクセス性が向上し、より包括的な治療管理が可能になります。米国遠隔医療協会（ATA）が2024年12月に発表した報告書によると、遠隔医療サービスとTMSの統合は2024年に前年比65%増加しました。

新しい治療分野への拡大：現在進行中の調査や臨床試験では、アルツハイマー病、脳卒中のリハビリテーション、依存症など、より幅広い疾患へのTMSの使用が検討されており、市場の範囲と潜在的な応用範囲が広がっています。アルツハイマー病協会（Alzheimer's Association）は2024年2月、アルツハイマー病に対するTMSを評価する3つの大規模臨床試験が第III相段階にあり、軽度から中等度の症例で有望な認知機能改善を示す予備的結果が得られたと報告しました。

当社のレポートには、実用的なデータと将来を見据えた分析が含まれており、ピッチの作成、ビジネスプランの作成、プレゼンテーションの構築、提案書の作成に役立ちます。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 経頭蓋磁気刺激装置市場：タイプ別

• 単一パルス経頭蓋磁気刺激装置
• 反復経頭蓋磁気刺激装置（rTMS）
• シータバースト経頭蓋磁気刺激装置（TBS）

第5章 経頭蓋磁気刺激装置市場：用途別

• 神経精神医学
• 神経学
• 研究開発
• 画像診断

第6章 経頭蓋磁気刺激装置市場：エンドユーザー別

• 病院
• 専門クリニック
• 研究機関
• 画像診断センター

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• BrainsWay
• Magstim
• Nexstim
• Salience
• MagVenture A/S
• Neuronetics
• Axilum Robotics

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Transcranial Magnetic Stimulators Market Size And Forecast

Transcranial Magnetic Stimulators Market size was valued at USD 1.13 Billion in 2024 and is projected to reach USD 2.16 Billion by 2032, growing at a CAGR of 8.45% from 2026 to 2032.

Transcranial Magnetic Stimulation (TMS) is a non-invasive medical procedure that uses electromagnetic fields to stimulate nerve cells in the brain. This technique involves placing a magnetic coil against the scalp, which generates a magnetic field that induces electric currents in specific brain areas. TMS is primarily used to modulate neuronal activity and has been widely researched for its therapeutic potential in various neurological and psychiatric conditions.

TMS has been most prominently applied in the treatment of major depressive disorder, especially in patients who do not respond to traditional therapies like medication and psychotherapy.

It is also being explored for treating other conditions such as anxiety disorders, post-traumatic stress disorder (PTSD), and chronic pain. The procedure is typically performed in an outpatient setting, with patients receiving multiple sessions over several weeks.

Additionally, TMS is used in research to study brain function and connectivity, helping to advance our understanding of neurological disorders.

The future scope of TMS is promising, with ongoing research aimed at expanding its therapeutic applications and improving its efficacy. Advances in technology may lead to more precise targeting of brain regions and individualized treatment protocols based on specific patient needs.

Transcranial Magnetic Stimulators Market is estimated to grow at a CAGR of 8.45% & reach US$ 2.16 Bn by the end of 2032

Global Transcranial Magnetic Stimulators Market Dynamics

The key market dynamics that are shaping the global transcranial magnetic stimulators market include:

Key Market Drivers

Increasing Prevalence of Depression and Mental Disorders: The rising number of individuals diagnosed with major depressive disorder and other mental health conditions drives the demand for effective treatments like TMS, particularly for patients resistant to conventional therapies. According to the World Health Organization (WHO), as of 2022, approximately 280 million people worldwide were living with depression. In the United States, the National Institute of Mental Health (NIMH) reported that in 2020, an estimated 21 million adults had at least one major depressive episode, representing 8.4% of all U.S. adults.

Technological Advancements: Continuous innovations in TMS technology, such as more precise targeting of brain areas and the development of portable devices, enhance treatment outcomes and expand the scope of TMS applications, fueling market growth. BrainsWay, another major player, launched its Deep TMS H7 Coil for treating adults with anxious depression in January 2024, expanding the applications of their technology.

Growing Awareness and Acceptance: Increasing awareness among healthcare providers and patients about the benefits and efficacy of TMS as a non-invasive treatment option leads to higher adoption rates, contributing to market expansion. The American Psychiatric Association (APA) updated its treatment guidelines for major depressive disorder in 2022, recommending TMS as a second-line treatment for patients who have not responded to at least one antidepressant medication.

Favorable Regulatory Environment: Supportive regulatory policies and approvals from health authorities, such as the FDA in the United States, facilitate the commercialization and adoption of TMS devices, encouraging market growth. The European Medicines Agency (EMA) issued updated guidelines for the clinical investigation of medical devices for TMS in 2024, streamlining the approval process for new TMS devices in the European market.

Key Challenges:

Limited Insurance Coverage: Insufficient reimbursement policies and limited insurance coverage for TMS treatments hinder patient access and uptake, posing a challenge for market growth.

Lack of Awareness and Training: A deficit in awareness among both patients and healthcare professionals, coupled with a need for specialized training to administer TMS, restricts its widespread implementation and acceptance.

Mixed Clinical Outcomes: Variability in treatment outcomes and the need for more extensive, long-term clinical trials to establish consistent efficacy across different patient populations can affect confidence in TMS as a reliable therapy.

Regulatory and Approval Hurdles: Stringent regulatory requirements and the lengthy approval process for new TMS devices and applications can delay market entry and innovation, challenging market expansion.

Key Trends

Personalized TMS Treatments: Advances in neuroimaging and AI are enabling the development of personalized TMS protocols tailored to individual brain patterns, improving treatment efficacy and patient outcomes. According to a study published in Nature Neuroscience in September 2024, personalized TMS protocols based on individual brain connectivity patterns showed a 40% improvement in treatment outcomes for major depressive disorder compared to standard protocols.

Integration with Digital Health Platforms: The incorporation of TMS therapy into digital health ecosystems, including telemedicine and remote monitoring, enhances patient accessibility and allows for more comprehensive treatment management. A report by the American Telemedicine Association (ATA) in December 2024 indicated that the integration of TMS with telemedicine services increased by 65% in 2024 compared to the previous year.

Expansion into New Therapeutic Areas: Ongoing research and clinical trials are exploring the use of TMS for a wider range of conditions, such as Alzheimer's disease, stroke rehabilitation, and addiction, broadening the market's scope and potential applications. The Alzheimer's Association reported in February 2024 that three large-scale clinical trials evaluating TMS for Alzheimer's disease were in phase III, with preliminary results showing promising cognitive improvements in mild to moderate cases.

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Transcranial Magnetic Stimulators Market Regional Analysis

Here is a more detailed regional analysis of the global transcranial magnetic stimulators market:

North America

North America is dominating the transcranial magnetic stimulators (TMS) market owing to the high prevalence of depression and other mental health disorders, advanced healthcare infrastructure, and strong regulatory support. The U.S. TMS market was valued at USD 400 Million in 2024 and was projected to grow at a CAGR of 8.5% from 2024 to 2032, according to data from the Medical Device Manufacturers Association (MDMA) released in March 2024.

The United States, in particular, has a large number of TMS service providers and ongoing clinical research, which contribute to market growth. The region benefits from favorable reimbursement policies and the widespread adoption of new medical technologies. The Anxiety and Depression Association of America (ADAA) stated in February 2024 that approximately 40% of patients with major depressive disorder in the U.S. were considered treatment-resistant, making them potential candidates for TMS therapy.

Asia Pacific

The Asia-Pacific region is experiencing rapid growth in the TMS market due to rising healthcare investments, expanding mental health awareness, and increasing prevalence of neurological disorders. According to a report by the Asia Pacific Medical Technology Association (APACMed) released in February 2024, the TMS market in the Asia-Pacific region was valued at USD 180 Million in 2024 and was projected to grow at a CAGR of 12.5% from 2024 to 2032.

Countries such as China, Japan, and South Korea are at the forefront of this growth, with improving healthcare infrastructure and growing adoption of advanced medical treatments. The China Medical Device Industry Association reported in December 2024 that the Chinese TMS market grew by 18% in 2024 compared to the previous year.

The region's large population base and increasing disposable income also contribute to market expansion. The Japanese Ministry of Health, Labour and Welfare announced in March 2024 a 15% increase in budget allocation for mental health services, including support for TMS treatment centers.

Global Transcranial Magnetic Stimulators Market: Segmentation Analysis

The Global Transcranial Magnetic Stimulators Market is Segmented on the basis of Type, Application, End-User, and Geography.

Transcranial Magnetic Stimulators Market Segmentation Analysis

Transcranial Magnetic Stimulators Market, By Type

• Single Pulse Transcranial Magnetic Stimulators
• Repetitive Transcranial Magnetic Stimulators (rTMS)
• Theta Burst Transcranial Magnetic Stimulators (TBS)

Based on Type, the Global Transcranial Magnetic Stimulators Market is bifurcated into Single Pulse Transcranial Magnetic Stimulators, Repetitive Transcranial Magnetic Stimulators (rTMS), and Theta Burst Transcranial Magnetic Stimulators (TBS). Repetitive transcranial magnetic stimulators (rTMS) currently dominate the transcranial magnetic stimulators market due to their widespread use in treating major depressive disorder and other psychiatric conditions. rTMS is well-established, with extensive clinical evidence supporting its efficacy, making it the preferred choice for many practitioners. Theta burst transcranial magnetic stimulators (TBS) are rapidly growing in popularity as the second-leading segment, driven by their shorter treatment times and emerging research indicating comparable or superior effectiveness to traditional rTMS, thus appealing to both patients and healthcare providers seeking efficient treatment options.

Transcranial Magnetic Stimulators Market, By Application

• Neuropsychiatry
• Neurology
• Research and Development
• Diagnostic Imaging

Based on Application, the Global Transcranial Magnetic Stimulators Market is bifurcated into Neuropsychiatry, Neurology, Research and Development, and Diagnostic Imaging. Neuropsychiatry is the dominating segment in the transcranial magnetic stimulators market, primarily due to the widespread adoption of TMS for treating major depressive disorder, treatment-resistant depression, and other psychiatric conditions. This application has gained significant traction due to strong clinical evidence and growing acceptance in the medical community. Neurology is the second rapidly growing segment, fueled by increasing research and clinical trials exploring the use of TMS for various neurological conditions such as stroke rehabilitation, Parkinson's disease, and chronic pain, expanding the potential therapeutic applications of TMS beyond mental health.

Transcranial Magnetic Stimulators Market, By End-User

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostic Imaging Centers

Based on End-User, the Global Transcranial Magnetic Stimulators Market is bifurcated into Hospitals, Specialty Clinics, Research Institutes, and Diagnostic Imaging Centers. Hospitals dominate the transcranial magnetic stimulators market as the primary end-users, leveraging their advanced infrastructure, broad patient base, and comprehensive medical services to provide TMS treatments, particularly for psychiatric and neurological disorders. Specialty Clinics are the second rapidly growing segment, driven by their focused expertise, personalized care, and increasing adoption of TMS for mental health treatments, making them a preferred choice for patients seeking specialized and accessible treatment options.

Transcranial Magnetic Stimulators Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Transcranial Magnetic Stimulators Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the transcranial magnetic stimulators market due to its advanced healthcare infrastructure, high prevalence of mental health disorders, and strong regulatory support, particularly in the United States. Europe follows as the second rapidly growing segment, driven by increasing mental health awareness, supportive healthcare policies, and significant investments in mental health services, with key countries like Germany, the United Kingdom, and France leading the adoption of TMS technology.

Key Players

The "Global Transcranial Magnetic Stimulators Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are BrainsWay, Magstim, Nexstim, Salience, MagVenture A/S, Neuronetics, Axilum Robotics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Transcranial Magnetic Stimulators Market Key Developments

• In March 2024, Neuronetics, Inc. received FDA clearance for its NeuroStar Advanced Therapy system, incorporating new software algorithms aimed at improving treatment outcomes for depression. This clearance is expected to boost the company's market share and drive adoption rates.
• In June 2024, BrainsWay Ltd. announced the successful completion of a Phase III clinical trial for its Deep TMS (dTMS) device targeting obsessive-compulsive disorder (OCD). This development is anticipated to broaden the application of dTMS and increase market penetration.
• In August 2024, Ybrain Inc. launched a new portable TMS device designed for home use. This innovation aims to make TMS therapy more accessible to patients and reduce the need for frequent clinic visits.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Transcranial Magnetic Stimulators Market, By Type

• Single Pulse Transcranial Magnetic Stimulators
• Repetitive Transcranial Magnetic Stimulators (rTMS)
• Theta Burst Transcranial Magnetic Stimulators (TBS)

5. Transcranial Magnetic Stimulators Market, By Application

• Neuropsychiatry
• Neurology
• Research and Development
• Diagnostic Imaging

6. Transcranial Magnetic Stimulators Market, By End-User

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostic Imaging Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• BrainsWay
• Magstim
• Nexstim
• Salience
• MagVenture A/S
• Neuronetics
• Axilum Robotics

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References